|
WO2021013733A1
|
|
Aryl-n-aryl derivatives for treating a rna virus infection
|
|
EP3766543A1
|
|
N-aryl derivatives for treating a rna virus infection
|
|
EP3669874A1
|
|
Quinoline derivatives for use in the treatment or prevention of cancer
|
|
EP3670659A1
|
|
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
EP3669873A1
|
|
Quinoline derivatives for use ine the traeatment of inflammation diseases
|
|
KR20200102412A
|
|
ABX196 for use in the treatment of bladder cancer
|
|
EP3594206A1
|
|
Phenyl-n-quinoline derivatives for treating a rna virus infection
|
|
EP3594205A1
|
|
Phenyl-n-aryl derivatives for treating a rna virus infection
|
|
EP3512557A1
|
|
Combinations including abx196 for the treatment of cancer
|
|
US2019185548A1
|
|
Antiviral polyclonal antibodies against ebola virus and the uses thereof
|
|
US2017226095A1
|
|
Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
|
|
EP3254691A1
|
|
Polyclonal antibodies for use in the prevention and/or treatment of ebola virus disease
|
|
AU2015203256A1
|
|
Compounds useful for treating cancer
|
|
EP3058940A1
|
|
Quinoline derivatives for use in the treatment or prevention of viral infection
|
|
EP3059591A1
|
|
Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
|
|
EP3059236A1
|
|
A new quinoline derivative for use in the treatment and prevention of viral infections
|
|
EP2975034A1
|
|
A quinoline derivative for the treatment of inflammatory diseases and AIDS
|
|
EP2974729A1
|
|
Quinoline derivatives for use in the treatment of inflammatory diseases
|
|
AU2014285733A1
|
|
Bicyclic compounds useful for treating diseases caused by retroviruses
|
|
AU2013202869A1
|
|
Increase of immune response and targeting by antigens and/or drug linkage
|
